Identification and Validation of Plasma Diagnostic Biomarkers for Multi-Cancer Based on Metabolomics: A Multi-Center Clinical Research and Validation Trial

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Multi-Cancer Group:

‣ Patients with a confirmed diagnosis based on the clinical gold standard.

⁃ Collection of plasma samples prior to treatment.

⁃ Availability of complete clinical data.

• Control Group:

‣ Individuals with no abnormalities in routine physical examinations and relevant clinical tests.

⁃ Age ≥ 45 years.

⁃ Availability of complete clinical data.

Locations
Other Locations
China
Beijing Friendship Hospital, Capital Medical University
RECRUITING
Beijing
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING
Beijing
Zhejiang Cancer Hospital
RECRUITING
Hangzhou
Hebei Tumor Hospital
RECRUITING
Shijiazhuang
Contact Information
Primary
Li Min, Ph.D.
minli@ccmu.edu.cn
+86 13552652141
Backup
Bilian Kang, Ph.D.
kbl@mail.ccmu.edu.cn
+86 18001218793
Time Frame
Start Date: 2024-03-29
Estimated Completion Date: 2025-04
Participants
Target number of participants: 2700
Treatments
Multi-cancer group
Patients diagnosed with cancer, including lung cancer,breast cancer,colorectal cancer,thyroid cancer,gastric cancer,cervical cancer,liver cancer,pancreatic cancer,cholangiocarcinoma,prostate cancer,esophageal cancer,ovarian cancer,renal cell carcinoma.
control group
Healthy controls
Sponsors
Leads: Beijing Friendship Hospital

This content was sourced from clinicaltrials.gov